课题基金 / 基金详情

THERAPEUTICS FOR COCAINE DEPENDENCE--NATURAL PRODUCTS

THERAPEUTICS FOR COCAINE DEPENDENCE--NATURAL PRODUCTS
可卡因依赖的治疗方法——天然产品
批准号:
2776931
负责人:
ROBERT R LUEDTKE
金额:
$6.3万
依托单位国家:
美国
项目类别:
财政年份:
1999
资助国家:
美国
项目状态:
已结题
起止时间:
1999-01-20 至 2000-11-30

项目摘要

项目成果

ROBERT R LUEDTKE的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Therapeutics for Cocaine Dependence: Natural Products Stimulation of dopamine receptor subtypes in the mesolimbic area of the brain appears to be directly associated with the cocaine-seeking behaviors. Therefore, the development of pharmacologic agents that selectively interact with dopamine receptor subtypes has the potential for yielding a pharmacotherapy for the various stages for cocaine addiction, including priming, reinforcement, craving, relapse and/or euphoria. Recent studies suggest that D-2 like dopamine receptor stimulation may mediate the incentive to seek further cocaine reinforcement, while D1-like dopamine receptor stimulation may attenuate reinforcement (Self et al., 1996). Natural plant products have served in the past as a rich source for the development of pharmacotherapeutic agents. Therefore, it is probably that natural compounds having dopaminergic activity can be identified by testing extracts of natural products. The goal of this grant application is to identify the extracts of natural products which have activity at D1- like and/or D2-like dopamine receptors. Initial pharmacologic characterization of the active extracts to determine the pharmacologic selectivity of the extract for each of the five D1-like (D1a and D1b) and D2-like (D2, D3, and D4) dopamine receptor subtypes and to determine whether the active component is an antagonist, agonist, partial agonists or inverse agonist at each of the D1-like and D2-like dopamine receptor subtypes. Purification and structural identification active components. The final goal of this application is to identify novel lead compounds that can be used for the development of natural, semi- synthetic or synthetic compounds that are either D1-like (D1a and D1b) dopamine receptor selective agonists or partial agonists or D3 dopamine receptor subtype selective antagonists.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Discovery of functionally selective Alzheimer's disease therapeutics
D3 Receptor Compounds for the Treatment of Psychostimulant Abuse
D3 Receptor Compounds for the Treatment of Psychostimulant Abuse
D3 Receptor Compounds for the Treatment of Psychostimulant Abuse
海外基金